Lymphocyte subpopulations: a potential predictor of a response in patients with immune thrombocytopenia

References

• Neunert C, Terrell DR, Arnold DM, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3:3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang C, Zhang L, et al. Biomarkers for immune thrombocytopenia. Biomark Res. 2015;3:19. doi:10.1186/s40364-015-0045-0
   PubMed Web of Science ®Google Scholar
• Cuker A, Prak E, Cines D. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost. 2015;41:395–404. doi:10.1055/s-0034-1544001
   PubMed Web of Science ®Google Scholar
• Lozano ML, Mingot-Castellano ME, Perera MM, et al. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Sci Rep. 2019;9:16680. doi:10.1038/s41598-019-53209-y
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185:503–513. doi:10.1111/bjh.15803
   PubMed Web of Science ®Google Scholar
• Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost. 2021;5; doi:10.1002/rth2.12592
   Web of Science ®Google Scholar
• Snell Taylor SJ, Nielson CM, Breskin A, et al. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther. 2021;38:2673–2688. doi:10.1007/s12325-021-01727-5
   PubMed Web of Science ®Google Scholar
• Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115:29–31. doi:10.1182/blood-2009-06-222448
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Battista M, et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol. 2006;34:571–572. doi:10.1016/j.exphem.2006.02.009
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Leven E, Imahiyerobo A, et al. Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. Br J Haematol. 2020;189; doi:10.1111/bjh.16426
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128:1625–1630. doi:10.1182/blood-2016-03-704734
   PubMed Web of Science ®Google Scholar
• Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135:472–490. doi:10.1182/blood.2019003599
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Pell J, Hill Q, et al. Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385:885–895. doi:10.1056/NEJMoa2100596
   PubMed Web of Science ®Google Scholar
• Lin X, Xu A, Zhou L, et al. Imbalance of T lymphocyte subsets in adult immune thrombocytopenia. IJGM Volume. 2021;14:937–947. doi:10.2147/IJGM.S298888
   Google Scholar
• Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74:5–17. doi:10.1016/j.cyto.2014.09.011
   PubMed Web of Science ®Google Scholar
• Zhao Z, Yang L, Yang G, et al. Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia. PLoS One. 2015;10:e0126601. doi:10.1371/journal.pone.0126601
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Li Y, et al. Immune dysregulation in primary immune thrombocytopenia patients. Hematology. 2018;23:510–516. doi:10.1080/10245332.2018.1435021
   PubMed Web of Science ®Google Scholar
• Rocha AMC, Souza C, Rocha GA, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011;96:1560–1564. doi:10.3324/haematol.2011.046417
   PubMed Web of Science ®Google Scholar
• Rong W, Yan-xiang Z, Shan-shan X, et al. Lymphocyte subsets in primary immune thrombocytopenia. Blood Coagul Fibrinolysis. 2014;25:816–819. doi:10.1097/MBC.0000000000000155
   PubMed Web of Science ®Google Scholar
• Goubran H, Hart C, Othman I, et al. Flow cytometry and immune thrombocytopenic purpura. Transfus Apher Sci. 2018;57:800–803. doi:10.1016/j.transci.2018.10.018
   PubMed Web of Science ®Google Scholar
• Oka S, Ono K, Nohgawa M. Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes. Int J Hematol. 2020;111:771–778. doi:10.1007/s12185-020-02847-4
   PubMed Web of Science ®Google Scholar
• Peng J, Ma S-H, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12:497–504. doi:10.1111/jth.12524
   PubMed Web of Science ®Google Scholar
• Feng R, Liu X, Zhao Y, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;182:305–307. doi:10.1111/bjh.14782
   PubMed Web of Science ®Google Scholar
• Yu Y, Hou Y, Zhao Y, et al. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021;194:191–194. doi:10.1111/bjh.17510
   PubMed Web of Science ®Google Scholar
• Beardsley MD, Ertem MD. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci. 1998;19:237–244. doi:10.1016/S0955-3886(98)00037-X
   PubMedGoogle Scholar
• Mahévas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013;88:858–861. doi:10.1002/ajh.23518
   PubMed Web of Science ®Google Scholar